Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Interest & Investment Income: 2014-2025

Historic Interest & Investment Income for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to $7.1 million.

  • Ascendis Pharma A's Interest & Investment Income fell 77.28% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $95.8 million, marking a year-over-year decrease of 14.61%. This contributed to the annual value of $27.7 million for FY2024, which is 41.26% down from last year.
  • Ascendis Pharma A's Interest & Investment Income amounted to $7.1 million in Q3 2025, which was down 88.68% from $62.3 million recorded in Q2 2025.
  • Ascendis Pharma A's Interest & Investment Income's 5-year high stood at $75.9 million during Q2 2022, with a 5-year trough of -$3.9 million in Q4 2024.
  • For the 3-year period, Ascendis Pharma A's Interest & Investment Income averaged around $27.3 million, with its median value being $30.4 million (2025).
  • Its Interest & Investment Income has fluctuated over the past 5 years, first soared by 43,363.98% in 2022, then plummeted by 115.96% in 2024.
  • Ascendis Pharma A's Interest & Investment Income (Quarterly) stood at $17.3 million in 2021, then slumped by 80.52% to $3.4 million in 2022, then spiked by 625.19% to $24.5 million in 2023, then plummeted by 115.96% to -$3.9 million in 2024, then tumbled by 77.28% to $7.1 million in 2025.
  • Its Interest & Investment Income stands at $7.1 million for Q3 2025, versus $62.3 million for Q2 2025 and $30.4 million for Q1 2025.